Scientists develop new strategy to overcome drug-resistant childh... ( A new drug combination could offer h...)

Scientists develop new strategy to overcome drug-resistant childhood cancer

Date:7/11/2012

A new drug combination could offer hope to children with neuroblastoma one of the deadliest forms of childhood cancer by boosting the effectiveness of a promising new gene-targeted treatment.

Researchers at The Institute of Cancer Research in London have found a way to overcome the resistance of cancer cells to a drug called crizotinib, which recently showed positive early results in its first trial in children with cancer.

Crizotinib has already been licensed by the US Food and Drug Administration for use in adult cancers, but early experience suggests tumours eventually stop responding to treatment, after developing additional mutations in the ALK gene targeted by the drug.

The paper, led by The Institute of Cancer Research in collaboration with the Dana-Farber Cancer Institute and Children's Hospital in Boston, publishes this week in the prestigious journal Cancer Cell. The study received funding from a variety of sources including The Neuroblastoma Society, Cancer Research UK, Sparks, the children's medical research charity and The Rooney Foundation.

In the study, scientists detailed their new strategy of combining crizotinib with a second class of drugs mTOR inhibitors to knock out the resistance of cancer cells.

Scientists identified the strategy after revealing for the first time the role played by the ALK cancer-causing gene in driving neuroblastoma, which accounts for 15 per cent of all the UK's childhood cancer deaths.

Neuroblastomas are cancers of the developing nervous system, and new drug combinations are desperately needed as aggressive forms of the disease are very difficult to treat with conventional chemotherapy.

Senior author Dr Louis Chesler, leader of the neuroblastoma drug development team at The Institute of Cancer Research and honorary consultant at The Royal Marsden NHS Foundation Trust, said: "With the first paediatric clinical trial reporting substantial resp
'/>"/>

Contact: ICR Science Communications Manager Jane Bunce
jane.bunce@icr.ac.uk
44-020-715-35106
Institute of Cancer Research
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. Scientists solving the mystery of human consciousness
2. Scientists uncover multiple faces of deadly breast cancer
3. Scientists identify major source of cells defense against oxidative stress
4. Scientists tailor cell surface targeting system to hit organelle ZIP codes
5. Scientists rewrite rulebook on breast cancer in landmark global study
6. Warwick scientists uncover how checkpoint proteins bind chromosomes
7. NIH scientists link quickly spreading gene to Asian MRSA epidemic
8. Joslin scientists identify important mechanism that affects the aging process
9. Scripps Research scientists show how memory B cells stay in class to fight different infections
10. Scientists Map Melanomas Genome
11. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases

Post Your Comments:

(Date:5/24/2013)... Compromise is often cited as crucial for relationships, ... sleep and comfort. However, many couples find themselves facing dilemmas ... this can cause added stress, lost sleep, and some resentment. ... common issues in their latest article on the subject. ... What to do When You Disagree on the Best Mattress ...

(Date:5/24/2013)... York, New York (PRWEB) May 24, 2013 ... the 2010 DePuy hip recall continue to move forward ... According to documents filed in California’s San Francisco ... been seeking an expedited trial of her DePuy hip ... (Tilman v. DePuy Orthopaedics, Inc., et al., No. CGC11508806; ...

(Date:5/24/2013)... 24, 2013 KC and Monica Craichy, Founders ... for FreeRide836. Their oldest sons, Kyle and Austin Craichy, will ... family and several professional kiteboarders. , KC Craichy said he ... has miraculously come together such that virtually everyone who planned ... , 20 kite boarders will meet at Matheson Hammock Park ...

(Date:5/24/2013)... Calif.) (PRWEB) May 24, 2013 ... House Appropriators and the California congressional delegation, joined ... restore sequestered industry user fees paid to the ... to ensure that future across-the-board cuts will not ... of the FY14 Agriculture, Rural Development and FDA ...

(Date:5/24/2013)... Teams of highly respected Alzheimer,s researchers failed to replicate ... of this brain disease when they were published last ... results, presented online Feb. 9, 2012, suggested that the ... buildup of beta amyloid plaques (Aβ) a pathological ... mice. According to the authors of the 2012 report, ...

Breaking Medicine News(10 mins):Health News:What’s The Best Bed Offers Mattress & Sleep Solutions for Opposite Couples 2 Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2 Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3 Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4 Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2 Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3 Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2 Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3 Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2 Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3

[0] What’s The Best Bed Offers Mattress & Sleep Solutions for Opposite Couples [0] DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case [0] FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa [0] California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 [0] Multiple research teams unable to confirm high-profile Alzheimer's study

... Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates ... , NEW YORK, June 19, 2009 Forest Laboratories, ... from two global multi-center Phase III studies of ceftaroline for ... data in each of the pivotal trials (FOCUS I and ...

... Kenneth A. May, former CEO of FedEx Kinko,s, has been ... Dimes, it was announced today. , , "Ken May is ... Prematurity Campaign," said Dr. Jennifer L. Howse, President of the March ... work towards our goal of giving every baby a healthy start ...

... changes , FRIDAY, June 19 (HealthDay News) -- A key ... by British researchers, who suggest that their finding may lead ... King,s College London and Imperial College London helps explain why ... are remodeled and how these changes contribute to chronic asthma. ...

... The Center for Laser Surgery, Washington, DC has announced the ... recently FDA approved, is the first cosmetic neurotoxin available alongside ... The Center for Laser Surgery was ... Dysport. As Washington, DC, Maryland and Virginia,s largest and most ...

... , WASHINGTON, June 19 The Department of Veterans Affairs ... its award-winning health care system, is poised to welcome nearly ... the country by expanding access to health care enrollment for ... , , "This incremental approach to expanding enrollment ensures ...

... should be treated as a priority if offenders held in ... research from the University of Adelaide, Australia. Adelaide researchers ... health of young offenders undertaken in the USA, UK, Europe ... have been published in this month,s Australian Journal of ...

Cached Medicine News:Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 2 Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 3 Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 4 Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 5 Health News:Dysport Available! New Wrinkle Treatment in Washington, DC Offers Botox Alternative 2 Health News:VA Reopening Health Care Enrollment to Thousands of Veterans 2 Health News:Young offenders' health critical to rehabilitation 2 Health News:Young offenders' health critical to rehabilitation 3

Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization Ken May Re-Elected for Second Term as Chairman of the Board of March of Dimes Asthma Discovery May Lead to Better Treatments Dysport Available! New Wrinkle Treatment in Washington, DC Offers Botox Alternative VA Reopening Health Care Enrollment to Thousands of Veterans Young offenders' health critical to rehabilitation

(Date:5/24/2013)... 2013 /PRNewswire-iReach/ -- Phoenix Houses of California ... organization, is hosting its tenth annual "Triumph For Teens" ... 6, 2013. More than 300 people are expected to ... residential treatment centers, family therapy, and prevention programs of ... have positive influences on the health and welfare of our ...

(Date:5/24/2013)... , May 24, 2013 Heska Corporation (NASDAQ: HSKA, ... and specialty products, announced today that Dr. Robert ... and Jason Napolitano , executive vice president ... Marcum MicroCap Conference, which is being held May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...

(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer"). On 20 May 2013, ...

[0] Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg [0] Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements

... Amgen (Nasdaq: AMGN ) today announced results ... treatment for advanced cancer patients with bone metastases in ... (zoledronic acid). These results underscore the efficacy profile of ... bone metastases from advanced breast cancer, as well as ...

... Dec. 10, 2010 Syndax Pharmaceuticals, Inc., a clinical-stage ... on entinostat, an orally bioavailable, highly selective, class I ... cancer. The data are being presented as oral poster ... 8 through December 12 in San Antonio Texas. ...

Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer

The Primus linear accelerator is a fully digital, technologically advanced radiation therapy treatment delivery system. It can be configured for delivery of routine, 3-D conformal or IMRT treatments....

... accelerators are true high-performance ... multileaf collimation and electronic ... enable you to perform ... IMRT treatments, as well ...

... Clinac EX accelerators ... with integrated Varian multileaf ... imaging systems which enable ... most advanced computer-driven IMRT ...

The Clinac C family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....

Medicine Products:

Primus Linear Accelerator Clinac 23EX Clinac 21EX Clinac C